(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 December 2011 (15.12.2011)

PCT

(10) International Publication Number
WO 2011/154724 A2

(51) **International Patent Classification**:
A61K 31/485 (2006.01) *A61K 47/34* (2006.01)
A61K 47/22 (2006.01) *A61K 9/00* (2006.01)

(21) **International Application Number**:
PCT/GB2011/051057

(22) **International Filing Date**:
6 June 2011 (06.06.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
1009549.5 8 June 2010 (08.06.2010) GB

(71) **Applicant** *(for all designated States except US)*: **RECKITT BENCKISER HEALTHCARE (UK) LIMITED** [GB/GB]; 103-105 Bath Road, Slough Berkshire SL1 3UH (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **NORTON, Richard L.** [US/US]; Reckitt Benckiser Pharmaceutical Inc., 2579 Midpoint Drive, Fort Collins, Colorado 80525 (US). **WATKINS, Andrew** [US/US]; Reckitt Benckiser Pharmaceutical Inc., 2579 Midpoint Drive, Fort Collins, Colorado 80525 (US). **ZHOU, Mingxing** [US/US]; Reckitt Benckiser Pharmaceutical Inc., 2579 Midpoint Drive, Fort Collins, Colorado 80525 (US).

(74) **Agents**: **HOLMES, Jeremy** et al.; Reckitt Benckiser Corporate Services Limited, Legal Department - Patents Group, Dansom Lane, Hull East Yorkshire HU8 7DS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2011/154724 A2

(54) **Title**: COMPOSITIONS

(57) **Abstract**: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.